Investigational Drug Information for Poziotinib

What is the drug development status for Poziotinib?

Poziotinib is an investigational drug.

There have been 21 clinical trials for Poziotinib. The most recent clinical trial was a Phase 2 trial, which was initiated on May 12^th 2022.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Breast Neoplasms, and Lung Neoplasms. The leading clinical trial sponsors are Spectrum Pharmaceuticals, Inc, Hanmi Pharmaceutical Company Limited, and National OncoVenture.

There are fifty US patents protecting this investigational drug and five hundred and seventy-six international patents.

Summary for Poziotinib

US Patents	50
International Patents	576
US Patent Applications	233
WIPO Patent Applications	253
Japanese Patent Applications	32
Clinical Trial Progress	Phase 2 (2022-05-12)
Vendors	66

Recent Clinical Trials for Poziotinib

Title	Sponsor	Phase
A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations	Spectrum Pharmaceuticals, Inc	Phase 3
Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer	M.D. Anderson Cancer Center	Phase 2
A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants	Spectrum Pharmaceuticals, Inc	Phase 1

See all Poziotinib clinical trials

Clinical Trial Summary for Poziotinib

Top disease conditions for Poziotinib

Top clinical trial sponsors for Poziotinib

See all Poziotinib clinical trials

US Patents for Poziotinib

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
Poziotinib		Compounds and methods for inhibiting vacuolar ATPase	University of Southern California (Los Angeles, CA)
Poziotinib		Gene fusions and gene variants associated with cancer	LIFE TECHNOLOGIES CORPORATION (Carlsbad, CA)
Poziotinib		Controlled release dosage form	TRIASTEK, INC. (Nanjing, CN)
Poziotinib		Crystalline forms of C.sub.21H.sub.22Cl.sub.2N.sub.4O.sub.2	Biomed Valley Discoveries, Inc. (Kansas City, MO) Vertex Pharmaceuticals Incorporated (Boston, MA)
Poziotinib		In vitro model for a tumor microenvironment	HemoShear, LLC (Charlottesville, VA)

International Patents for Poziotinib

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
Poziotinib	Australia	AU2014254394	2033-04-17
Poziotinib	China	CN105378110	2033-04-17
Poziotinib	China	CN106414768	2033-04-17
Poziotinib	European Patent Office	EP2986736	2033-04-17
Poziotinib	European Patent Office	EP3122901	2033-04-17